BioBlast reports Q2 results

|About: Bio Blast Pharma (ORPN)|By:, SA News Editor

BioBlast Pharma (NASDAQ:ORPN) Q2 results: Revenues: $0; Operating Expenses: $1.1M (+729.9%); Net Loss: ($1.1M) (-725.2%); Loss Per Share: ($0.10) (-400.0%); Quick Assets: $4.2M (+999%); Cash Burn: ($0.7M) (-690.5%).

No financial guidance given.